Recurrent Malignant Glioma Market Size to Reach USD 2.3 Billion by 2035, Impelled by Advancements in Early Detection

May 19, 2025 | Healthcare

VIEW FULL TABLE OF CONTENTS

Recurrent Malignant Glioma Market Outlook 2025-2035:

The recurrent malignant glioma market size reached a value of USD 1.5 Billion in 2024. Looking forward, the market is expected to reach USD 2.3 Billion by 2035, exhibiting a growth rate (CAGR) of 4.29% during 2025-2035. The market is driven by the increasing demand for immunotherapies, like checkpoint inhibitors and therapeutic vaccines, which work by harnessing the immune system's potential to target tumor cells. Additionally, the development of targeted therapies and innovative treatments is further propelling the market growth.

Advances in Early Detection and Diagnostic Technologies: Driving the Recurrent Malignant Glioma Market

Advances in early detection and diagnostic technologies are significantly driving growth in the recurrent malignant glioma market, transforming how this aggressive brain tumor is identified, monitored, and managed. Moreover, recent technological breakthroughs are enhancing early and accurate detection, improving patient outcomes and expanding market opportunities. One of the most impactful advancements is the development of imaging technologies. High-resolution magnetic resonance imaging (MRI), combined with advanced techniques like perfusion-weighted imaging and spectroscopy, provides detailed insights into tumor biology and progression. Positron emission tomography (PET) imaging, using tracers such as fluorodeoxyglucose (FDG) or amino acid derivatives, further improves diagnostic accuracy by differentiating tumor recurrence from treatment-related changes like radiation necrosis. Besides this, liquid biopsies are emerging as a game-changer in early detection. These non-invasive tests analyze circulating tumor DNA (ctDNA) and other biomarkers in blood or cerebrospinal fluid, offering real-time insights into tumor dynamics and genetic alterations. Liquid biopsies enable early identification of recurrence and facilitate personalized treatment strategies, a critical need in managing gliomas. Moreover, genetic and molecular diagnostics are also transforming the landscape. Next-generation sequencing (NGS) and biomarker analysis enable clinicians to identify actionable mutations, such as IDH1 or MGMT promoter methylation, guiding targeted therapy decisions. These innovations not only improve clinical outcomes but also boost the recurrent malignant glioma market by driving demand for advanced diagnostics, fostering therapeutic innovations, and facilitating precision medicine approaches.

Development of Novel Therapies and Pharmacological Treatments: Contributing to Market Expansion

The development of novel therapies and pharmacological treatments is a critical driver of expansion in the recurrent malignant glioma market, addressing the significant unmet needs associated with this aggressive and often fatal brain tumor. Traditional treatment options, including surgery, radiation, and chemotherapy, have limited efficacy in controlling recurrent disease. This has spurred innovation in targeted therapies, immunotherapies, and advanced drug delivery systems to improve patient outcomes. Targeted therapies are revolutionizing the treatment landscape by addressing the molecular underpinnings of malignant gliomas. Drugs targeting specific mutations, such as IDH1 inhibitors or agents modulating MGMT promoter methylation, offer personalized treatment options. Furthermore, small-molecule inhibitors targeting signaling pathways like EGFR and VEGF are under investigation, aiming to curb tumor growth and angiogenesis. Immunotherapy is another transformative area driving market growth. Approaches such as immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1 antibodies), tumor vaccines, and adoptive T-cell therapies are showing promise in enhancing the immune system’s ability to combat gliomas. Oncolytic viruses, which selectively infect and destroy cancer cells, are also emerging as an innovative strategy in clinical trials. Advances in drug delivery systems, including nanoparticles and biodegradable wafers, are improving therapeutic precision by enabling localized and sustained drug release at the tumor site. Besides this, collaboration between academic institutions, pharmaceutical companies, and regulatory bodies has accelerated the development pipeline for glioma therapies. Furthermore, regulatory incentives, such as orphan drug designations and fast-track approvals, encourage investment in innovative treatments for recurrent gliomas.

Emerging Therapies in Recurrent Malignant Glioma Market

OKN-007: Oblato

OKN-007, also known as Oklahoma Nitrone 007, is an experimental medication that works in multiple ways to treat recurrent malignant gliomas. OKN-007 inhibits the action of TGF-β1, affecting the extracellular matrix. This can inhibit cell growth and angiogenesis while increasing apoptosis. Additionally, OKN-007 can restore the tumor microenvironment, thereby enhancing glioblastoma cell death and tumor growth regression. OKN-007 can also decrease the expression of VCAN and ADAMTS2, which are highly expressed in some cancers and gliomas.

Drug Name	Company Name	MOA	ROA
OKN-007	Oblato	Oxygen radical scavengers; Sulfatase inhibitors	Intravenous

Detailed list of emerging therapies in Recurrent Malignant Glioma is provided in the final report.

Key Players in Recurrent Malignant Glioma Market:

The key players in the Recurrent Malignant Glioma market who are in different phases of developing different therapies are Oblato and Others.

Key Players

Regional Analysis:

The major markets for recurrent malignant glioma include the United States, Germany, France, the United Kingdom, Italy, Spain, and Japan. According to projections by IMARC, the United States has the largest patient pool for recurrent malignant glioma while also representing the biggest market for its treatment. This can be attributed to the rising popularity of drugs targeting genetic mutations and signaling pathways specific to gliomas, along with immune checkpoint inhibitors, which are fueled by robust clinical trials and collaborations between biotech companies and academic institutions.

Moreover, one of the primary drivers is the rapid advancement in diagnostic and therapeutic technologies. High-resolution imaging techniques, such as MRI with advanced sequences and PET imaging, have improved the ability to detect and monitor recurrent gliomas, enabling timely intervention.

Besides this, increased government funding and support for brain tumor research, along with regulatory incentives like orphan drug designations, have also spurred the development of novel therapies. Strong healthcare infrastructure in the U.S. and rising awareness among patients and providers further drive market growth, making it a global leader in managing recurrent malignant gliomas.

Recent Developments in Recurrent Malignant Glioma Market:

In April 2023, Oblato, Inc. announced the first enrollment of recurrent high-grade glioma patients in a Phase 1 clinical trial in the United States using an oral formulation of its proprietary substance OKN-007. This represents the first use of oral OKN-007 in glioblastoma clinical trials. In conjunction with the continuing clinical development of an injectable formulation, this Phase 1 trial is intended to broaden the prospect of a new medication approval for the treatment of glioblastoma.

Key information covered in the report.

Base Year: 2024
Historical Period: 2019-2024
Market Forecast: 2025-2035

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the recurrent malignant glioma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the recurrent malignant glioma market
Reimbursement scenario in the market
In-market and pipeline drugs

Competitive Landscape:

This report offers a comprehensive analysis of current recurrent malignant glioma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. Across the six major continents and 100+ countries, we work alongside our business partners as one team with a common ambition to achieve unparallelled results, gain a competitive edge, and transform industries. IMARC Group excels in understanding its clients’ business priorities and delivering tailored solutions that drive meaningful outcomes. Our client base spans over 3,000 organizations in the private, public, and social sectors, ranging from high-growth startups to Fortune 500 companies.

Contact US

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Phone Number: - +1 631 791 1145, +91-120-433-0800

Need more help?

Speak to our experienced analysts for insights on the current market scenarios.
Include additional segments and countries to customize the report as per your requirement.
Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
For further assistance, please connect with our analysts.

Recurrent Malignant Glioma Market Size to Reach USD 2.3 Billion by 2035, Impelled by Advancements in Early Detection

Purchase Options Discount
Offer

Inquire Before Buying

Benefits of Customization

Personalize this research
Triangulate with your data
Get data as per your format and definition
Gain a deeper dive into a specific application, geography, customer, or competitor
Any level of personalization

Speak to an Analyst

Request Brochure

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

IMARC did an outstanding job in preparing our study. They were punctual and precise, delivering all the data we required in a clear and well-organized format. Their attention to detail and ability to meet deadlines was impressive, making them a reliable partner for our project.

I wanted to express my sincere appreciation for your efforts in handling this matter. Your dedication and commitment have truly been commendable. It is evident that you have put in a tremendous amount of hard work and expertise into resolving the issues at hand. I would also like to take this opportunity to inform you that we are greatly interested

Overall, the deliverable was well organized and my experience with the project team was good. In particular, I appreciated how they responded when I requested additional information and the Japanese version.

The IMARC team were extremely professional and very cooperative. The team were also extremely flexible in making changes and modifications wherever required. The entire experience right from project kick-off to after sales support was fruitful and smooth.

I’d like to express my gratitude for the work you accomplished with the industry report. The way you responded to the requirements and delivered under tight timelines shows your expertise, exceptional work ethic and commitment to your customer’s success. The entire team and company are incredibly thankful for your dedication. Once again, thank you

The market reports from IMARC have been instrumental in guiding our business strategies. We found the reports comprehensive and data-driven, which helped us make informed decisions. The detailed insights and actionable data have consistently provided us with a competitive edge in a rapidly changing alcohol market.

One of the best things about IMARC is their flexibility and predisposition to tailor the reports and adapt to our needs. They are not just great in their researching and consulting solutions, but their service is unparallelled. We’ve worked with them a couple of times and we will keep working with them in future projects.

We recently commissioned multiple market research reports from IMARC, and the insights we received were invaluable. The depth of analysis, accuracy of data, and actionable recommendations have greatly enhanced our strategic decision-making.

The market estimates provided by your team were pretty much in line with what we were theorizing internally. Really appreciate the work on this.

The sale account manager and the service was excellent. The data and market trends gathered from the report was insightful and really assisted while planning future product and growth strategies.

The report is excellent and has good amount of data and our team is extremely happy with the information provided.

Thank you very much for your cooperation and post purchase support. We were really happy with the final deliverable, and the takeaways from the report.